IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory iNHL. Adults with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) after ≥2 lines of thera...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia Jg. 20; S. S278
Hauptverfasser:	Jacobson, Caron A., Chavez, Julio C., Sehgal, Alison R., William, Basem M., Munoz, Javier, Salles, Gilles, Casulo, Carla, Munshi, Pashna N., Maloney, David G., Vos, Sven de, Reshef, Ran, Leslie, Lori A., Yakoub-Agha, Ibrahim, Oluwole, Olalekan O., Fung, Henry C., Plaks, Vicki, Yang, Yin, Lee, Jennifer, Avanzi, Mauro P., Neelapu, Sattva S.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Elsevier Inc 01.09.2020
Schlagworte:	CAR T cell therapy chimeric antigen receptor IBCL indolent B-cell lymphoma IBCL chimeric antigen receptor CAR T cell therapy indolent B-cell lymphoma
ISSN:	2152-2650, 2152-2669
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!